Email Page Print Page

News & Media

These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released via email or RSS.

Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011

2014 Archives

Dec 10, 2014
Website and Mobile App Offer Comprehensive Array of Information and Resources to Support Patients and Their Families
Nov 5, 2014
BUNAVAIL™ (buprenorphine and naloxone) buccal film now available by prescription for the maintenance treatment of opioid dependence
Nov 3, 2014
BUNAVAIL Is the First and Only Buccal Film Formulation of Buprenorphine and Naloxone for the Maintenance Treatment of Opioid Dependence
Oct 28, 2014
Complementary to BUNAVAIL™; Potential to Leverage Current Addiction Sales Force
Oct 6, 2014
Conference Call Scheduled for Tuesday, October 7 at 8:00 AM Eastern Time
Sep 3, 2014
September 4th ceremony celebrates 2014 accomplishments including FDA approval and anticipated commercial launch of BUNAVAIL
Aug 12, 2014
BEMA Buprenorphine on track for late 2014 or early 2015 NDA filing by partner Endo Pharmaceuticals
Aug 7, 2014
BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) approved by FDA for the maintenance treatment of opioid dependence; US launch planned for late Q3
Jul 7, 2014
IN OPIOID-EXPERIENCED PATIENTS WITH CHRONIC PAIN Pre-NDA meeting scheduled with FDA in July
Jun 11, 2014
President and CEO Mark A. Sirgo Describes BUNAVAIL™ Delivery, Competitive Advantages, Market Size and Patient Need
Jun 9, 2014
First and Only FDA-Approved Buccal Film Formulation of Buprenorphine and Naloxone to Compete in the $1.7 Billion and Growing U.S. Opioid Dependence Market
Jun 6, 2014
First and Only FDA-Approved Buccal Film Formulation of Buprenorphine and Naloxone to Compete in the $1.7 Billion and Growing U.S. Opioid Dependence Market
May 8, 2014
BUNAVAIL PDUFA date June 7, 2014; Pre-launch activities underway to support an anticipated late Q3 2014 launch